Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
284lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Learning paths
Pick a track — progress rings update as you complete lessons.
6 lessons
7mResearchAdvanced
Orforglipron vs Weekly Injectable GLP-1s: How the Oral Option Changes Access
The first small-molecule oral GLP-1 option removes injection training and cold-chain handling, but daily dosing creates a different adherence job.
8mResearchAdvanced
September 2026 Peptide Research Signals: Access, Pipelines, and Quality
The loudest peptide stories are moving at different speeds. PCAC recommendations await FDA action, oral GLP-1 access is real, and the next obesity programs still have filing or review milestones ahead.
8mResearchAdvanced
Amycretin Beginner's Guide: Novo's GLP-1 + Amylin Dual Agonist
Amycretin puts GLP-1 and amylin in one molecule — with both a pill and a weekly shot in development. Here's the beginner map before Phase 3 ladders finalize.
9mProtocolsIntermediate
Amycretin Dosing Guide: Oral Daily and Weekly Subcutaneous Protocols
Amycretin is Novo's dual GLP-1 + amylin molecule with both oral and injectable programs. Here's the early dosing map and why Phase 3 is the next SEO wave.
8mProtocolsIntermediate
Orforglipron Dosing Guide: Oral GLP-1 Titration to 6, 12, and 36 mg
Orforglipron is Lilly's once-daily oral small-molecule GLP-1. Here's the titration ladder searchers want — 1 mg start, step-ups every four weeks, and Phase 3 maintenance doses.
9mPolicyAdvanced
Oral GLP-1s Are Here: What the Foundayo FDA Approval Means for the Peptide Community
For years, GLP-1 therapy meant a weekly injection. The FDA just changed that. Foundayo is the first oral GLP-1 approved for weight management, and the implications for the peptide community go far beyond convenience.
Also available at /blog for legacy links.